Physician profile
Derek K Holcombe
NPI 1841203833
$2,484.83
in general payments reported to CMS, 2019-2025
21 companies · $765 in 2025
The $765 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.01 · 2020: $65.73 · 2021: $303 · 2022: $341 · 2023: $538 · 2024: $404 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $608.60 | 2019-2025 | |
| Janssen Biotech, INC. | $405.60 | 2019-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $292.60 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $269.61 | 2021-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.84 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $122.15 | 2019-2024 | Entyvio |
| Madrigal Pharmaceuticals | $109.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $68.69 | 2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $61.53 | 2023 | |
| Celgene Corporation | $60.17 | 2022-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $36.10 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $34.35 | 2020-2022 | |
| Evoke Pharma, INC. | $32.27 | 2022-2023 | Gimoti |
| Genzyme Corporation | $27.00 | 2022 | |
| Pfizer INC. | $23.02 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.23 | 2025 | Wegovy |
| Celltrion USA INC. | $15.85 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $15.44 | 2025 | Rebyota |
| Conmed Corporation | $13.93 | 2023 | Conmed Hemostasis, Conmed Dilation |
| Gilead Sciences, INC. | $13.31 | 2024 | |
| Organon LLC | $12.75 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Holcombe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.